Clinical Trials in Metastatic Uveal Melanoma: Current Status
- PMID: 33447587
- PMCID: PMC7772871
- DOI: 10.1159/000508383
Clinical Trials in Metastatic Uveal Melanoma: Current Status
Abstract
Background: Uveal melanoma is a rare subtype of melanoma. Prognosis and survival rates for patients with metastatic uveal melanoma remain poor. No current FDA-approved standard of care therapy is available for patients with metastatic uveal melanoma. Thus, clinical trials are essential for the development of new therapies and to provide patients hope for improved survival and outcomes.
Summary: In this article, we review clinical trials identified on the database https://clinicaltrials.gov that are open and enrolling patients with metastatic uveal melanoma as of November 26, 2019. This search produced 17 active trials involving liver-directed therapy, CNS-directed therapy, and systemic therapy with immunotherapy, targeted therapy, or oncolytic virus therapy. Here, we discuss liver and CNS-directed therapy as well as systemic targeted therapy and oncolytic virus therapy. Immunotherapy clinical trials are discussed in a companion review article by Dr. Marlana Orloff.
Key messages: Various novel therapeutic targets and immunomodulatory approaches are on the horizon for patients with metastatic uveal melanoma and may yield incremental therapeutic benefit. Selecting a clinical trial must be individualized and made jointly with the patient and his/her oncologist.
Keywords: Clinical trials; Liver-directed therapy; Metastasis; Oncology; Uveal melanoma.
Copyright © 2020 by S. Karger AG, Basel.
Conflict of interest statement
Tamara Sussman has no conflicts of interest to declare. Pauline Funchain receives consultant fees from Eisai and research funding from Pfizer. Arun Singh receives consulting fees from Eckert and Zeigler, and Isoaid; advisory board meeting with Immunocore; and stock options with Aura.
Figures
References
-
- Aronow ME, Topham AK, Singh AD. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013) Ocul Oncol Pathol. 2018 Apr;4((3)):145–51. [cited 2019 Aug 14] Available from: http://www.ncbi.nlm.nih.gov/pubmed/29765944. - PMC - PubMed
-
- Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011 Sep;118((9)):1881–5. [cited 2019 Aug 14] Available from: https://linkinghub.elsevier.com/retrieve/pii/S016164201100073X. - PubMed
-
- Kujala E, Ma¨kitie T, Kivela¨ T. Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma. Investig Opthalmology Vis Sci. 2003 Nov 1; [cited 2019 Aug 14];44(11):4651. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14578381. - PubMed
-
- Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26 [Internet] Arch Ophthalmol. 2005 Dec 1; [cited 2019 Aug 14]; 123(12): 1639–43. Available from: http://archopht.jamanetwork.com/article.aspx?doi=10.1001/archopht.123.12.... - PubMed
-
- Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009 Jul;148((1)):119–27. [cited 2019 Aug 14] Available from: http://www.ncbi.nlm.nih.gov/pubmed/19375060. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
